Who owns CDT Equity Inc. (CDT)? Elite investor 13F holders
2 tracked elite investors reported holding CDT Equity Inc as of 2026-06-30, including Saba Capital, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Saba Capital | CDT EQUITY INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 12546.00 USD | 765000.000000 | Shares | hold | Original filing |
| D.E. Shaw | CDT EQUITY INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 4125.00 USD | 375000.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.